All In Biotech

Drug Trial Radar · NCT04832880

Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)

Factorial, Multicentric, Randomized Clinical Trial of Remdesivir and Immunotherapy in Combination With Dexamethasone for Moderate COVID-19 (the AMMURAVID Trial)

Last checked: Nov 20, 2026Latest source record: Apr 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 4,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

4,000

Planned (sponsor's estimate)

Start

Apr 6, 2021

Primary completion

Mar 2022

Study completion Dec 2022

Sponsor

Lead sponsor
ASST Fatebenefratelli SaccoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: In the current worldwide medical emergency, a rapid identification of effective therapeutic strategy is crucial. So far, therapy with dexamethasone, remdesivir and baricitinib have been associated with evidence of impact on the clinical impact on COVID-19, but the effect of baricitinib and remdesivir in combination with dexamethasone. The AAMMURAVID trial is endorced and supported by the Italian Regulatory agency (AIFA-Agenzia Italiana del Farmaco)

Conditions

  • Covid19

Interventions

  • Baricitinib Oral Tablet [Olumiant]Drug

    Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.

  • RemdesivirDrug

    Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10

  • DexamethasoneDrug

    Intravenous dexamethasone 6 mg for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevention of very severe respiratory failure or mortalityTime frame: Day1-Day 28

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Ospedali Riuniti delle Marche

    Ancona, Italy

  • Ospedale Parini

    Aosta, Italy

  • Ospedale SS Annunziata -Chieti

    Chieti, Italy

  • Ospedale S Anna

    Como, Italy

  • Ospedale di Ferrara

    Ferrara, Italy

  • Ospedale di Firenze and Empoli

    Florence, Italy

  • Ospedali Galliera

    Genova, Italy

  • H Goretti

    Latina, Italy

  • Ospedale Manzoni

    Lecco, Italy

  • Ospedale di Legnago

    Legnago, Italy

  • Ospedale di Legnano

    Legnano, Italy

  • ASST Fatebenefratelli-Sacco

    Milan, Italy

  • ASST Santi Paolo e Carlo

    Milan, Italy

  • IRCCS San Raffaele

    Milan, Italy

  • Ospedale di Perugia

    Perugia, Italy

  • Ospedale San Salvatore

    Pesaro, Italy

  • Ospedali di Prato e Pistoia

    Prato, Italy

  • Policlinico Tor Vergata

    Roma, Italy

  • Ospedale Cattinara e Maggiore

    Trieste, Italy

  • Ospedale di Udine

    Udine, Italy

  • Azienda Ospedaliera Integrata -Verona

    Verona, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.